ASX

21.67

+3.44%↑

FROG

46.89

+9.94%↑

PII

54.4

+1.63%↑

NWL

3.43

+3.63%↑

BFLY.US

4.03

+5.5%↑

ASX

21.67

+3.44%↑

FROG

46.89

+9.94%↑

PII

54.4

+1.63%↑

NWL

3.43

+3.63%↑

BFLY.US

4.03

+5.5%↑

ASX

21.67

+3.44%↑

FROG

46.89

+9.94%↑

PII

54.4

+1.63%↑

NWL

3.43

+3.63%↑

BFLY.US

4.03

+5.5%↑

ASX

21.67

+3.44%↑

FROG

46.89

+9.94%↑

PII

54.4

+1.63%↑

NWL

3.43

+3.63%↑

BFLY.US

4.03

+5.5%↑

ASX

21.67

+3.44%↑

FROG

46.89

+9.94%↑

PII

54.4

+1.63%↑

NWL

3.43

+3.63%↑

BFLY.US

4.03

+5.5%↑

Search

Diversified Healthcare Trust

Abierto

SectorÍndices

6.62 -2.22

Resumen

Variación precio

24h

Actual

Mínimo

6.6

Máximo

6.82

Métricas clave

By Trading Economics

Ingresos

143M

-21M

Ventas

-9.1M

380M

BPA

-0.063

Rentabilidad por dividendo

0.6

Margen de beneficios

-5.591

EBITDA

190M

136M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+9.52% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.60%

4.60%

Próximas Ganancias

4 may 2026

Fecha Próximo Dividendo

14 may 2026

Próxima Fecha de Ex Dividendo

21 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

114M

1.6B

Apertura anterior

8.84

Cierre anterior

6.62

Noticias sobre sentimiento de mercado

By Acuity

23%

77%

1 / 26 Clasificación en Indices

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Diversified Healthcare Trust Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 mar 2026, 23:31 UTC

Acciones populares

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Ganancias

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 abr 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Adquisiciones, fusiones, absorciones

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Ganancias

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Charlas de Mercado
Ganancias

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Charlas de Mercado

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Adquisiciones, fusiones, absorciones

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Charlas de Mercado

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Ganancias

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Ganancias

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Ganancias

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Ganancias

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Ganancias

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Ganancias

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Ganancias

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Ganancias

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Charlas de Mercado
Ganancias

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Ganancias

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Ganancias

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Ganancias

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Ganancias

Nike CEO: Converse Remains Important to Portfolio

Comparación entre iguales

Cambio de precio

Diversified Healthcare Trust previsión

Precio Objetivo

By TipRanks

9.52% repunte

Estimación a 12 Meses

Media 7.25 USD  9.52%

Máximo 8.5 USD

Mínimo 6 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Diversified Healthcare Trust Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

1

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.34 / 3.02Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

1 / 26 Clasificación en Índices

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Diversified Healthcare Trust

DHC is a real estate investment trust, or REIT, focused on owning high-quality healthcare properties located throughout the United States. DHC seeks diversification across the health services spectrum by care delivery and practice type, by scientific research disciplines and by property type and location. As of December 31, 2023, DHC's approximately $7.2 billion portfolio included 371 properties in 36 states and Washington, D.C., occupied by approximately 500 tenants, and totaling approximately 8.6 million square feet of life science and medical office properties and more than 27,000 senior living units. DHC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with over $41 billion in assets under management as of December 31, 2023 and more than 35 years of institutional experience in buying, selling, financing and operating commercial real estate. DHC is headquartered in Newton, MA.
help-icon Live chat